EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience

Fernanda Costa Svedman, Karin Holmsten, Faith Jawdat, Wehazit Hailom, Daniel Alm, Vitali Grozman, Anders Ullén

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02465-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Fernanda Costa Svedman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. fernanda.costa-svedman@regionstockholm.se. Hauptthemen laut MEDLINE: Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Standard treatment options for patients with metastatic urothelial cancer (mUC) include systemic platinum-based chemotherapy, immunotherapy, antibody-drug-conjugates, and targeted therapy. Oligometastatic disease (OMD) may be an intermediate state between localized and generalized cancer. The best treatment strategy for OMD and oligoprogressive (OPD) disease is poorly studied in mUC but local stereotactic body radiation therapy (SBRT) could be an option to avoid or delay systemic treatment. The aim of this study was to assess the efficacy and feasibility of SBRT given in a real-world patient population.

Methods

All patients with mUC treated with SBRT at Karolinska University Hospital, Stockholm, Sweden between 2009 and 2022 were included in this study. Baseline clinical characteristics, treatment data, SBRT dosimetry data and treatment outcome were collected retrospectively. The study endpoints were local control rate (LCR), progression-free-survival (PFS), overall survival (OS) and feasibility of SBRT.

Results

In total 39 patients were treated with SBRT. The median follow-up was 25.6 months. The LCR was 82%. PFS and OS were 4.1 and 26.2 months, respectively. Treatment was well tolerated; all patients but one (treatment related pain) completed the planned SBRT. Number of metastases irradiated with SBRT was significantly associated with outcome; patients with only one irradiated lesion had more favourable PFS compared to individuals with 2 or more metastases (HR 4.12, 95% CI: 1.81–9.38, p = 0.001). A subgroup of patients (15%) achieved a sustained long-term survival benefit and never required systemic treatments after SBRT.

Conclusions

SBRT was well tolerated and associated with high LCR. A subpopulation of patients with single metastatic lesion achieved long-term OS and never required subsequent systemic treatment after SBRT. Prospective randomized studies are warranted to discover treatment predictive biomarkers and to investigate the role of SBRT in oligometastatic UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overSurvival RateUrologic NeoplasmsNeoplasm MetastasisAdultUrinary Bladder Neoplasms

Stichwörter der Autor:innen

OligometastaticOligoprogressiveSBRTStereotactic body radiation therapyUrothelial cancer

Autor:innen und Institutionen

  • Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. fernanda.costa-svedman@regionstockholm.se.
  • Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Theme Cancer, Karolinska University Hospital, Stockholm, 171 76, Sweden. fernanda.costa-svedman@regionstockholm.se.
  • Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Department of Oncology, Capio S:t Göran Hospital, Stockholm, Sweden.
  • Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Theme Cancer, Karolinska University Hospital, Stockholm, 171 76, Sweden.
  • Department of Radiation Oncology, Karolinska University Hospital, Stockholm, Sweden.

Förderung

  • Karolinska Institute

Zitieren

APA

Svedman, F. C., Holmsten, K., Jawdat, F., Hailom, W., Alm, D., Grozman, V., & Ullén, A. (2024). Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience. Radiation Oncology. https://doi.org/10.1186/s13014-024-02465-y

Vancouver

Svedman FC, Holmsten K, Jawdat F, Hailom W, Alm D, Grozman V, et al. Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience. Radiation Oncology. 2024. doi:10.1186/s13014-024-02465-y

BibTeX
@article{Svedman2024,
  author = {Svedman, Fernanda Costa and Holmsten, Karin and Jawdat, Faith and Hailom, Wehazit and Alm, Daniel and Grozman, Vitali and Ullén, Anders},
  title = {Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02465-y}
}
Kostenlos starten →